Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	681.88	812.69	866.39	819.98	496.58	547.18
Short-Term Investments	1,689	1,627	1,326	1,616	1,378	988.98
Cash & Cash Equivalents	2,371	2,439	2,192	2,436	1,874	1,536
Cash Growth	14.52%	11.27%	-9.98%	29.94%	22.02%	41.69%
Receivables	321.38	327.79	237.96	198.57	102.41	43.01
Inventory	93.99	89.15	128.96	86.36	75.2	56.35
Other Current Assets	201.96	126.38	132.92	88.08	562.77	80.34
Total Current Assets	2,989	2,983	2,692	2,809	2,615	1,716
Property, Plant & Equipment	718.93	725.79	738.63	733.63	706.51	646.38
Long-Term Investments	49.39	49.39	49.39	40.89	40.73	14.83
Other Long-Term Assets	67.46	72	66.09	60.2	45.05	18.07
Total Long-Term Assets	835.78	847.18	854.11	834.73	792.28	679.27
Total Assets	3,824	3,830	3,546	3,643	3,407	2,395
Accounts Payable	78.15	55.52	98.09	73.43	51.97	49.88
Deferred Revenue	262.36	290.93	235.9	301.84	352.3	396.2
Current Debt	41.67	41.51	41.97	40.55	36.87	27.69
Other Current Liabilities	559.53	579.83	391.96	279.89	144.13	-121.18
Total Current Liabilities	941.71	967.79	767.92	695.71	585.27	352.59
Long-Term Debt	1,260	1,264	1,278	957.04	484.32	276.14
Other Long-Term Liabilities	1,842	1,819	1,658	1,402	1,321	327.71
Total Long-Term Liabilities	3,102	3,083	2,937	2,359	1,806	603.85
Total Liabilities	4,044	4,051	3,705	3,055	2,391	956.44
Total Debt	1,301	1,305	1,320	997.59	521.19	303.82
Debt Growth	-1.45%	-1.13%	32.34%	91.41%	71.54%	912.74%
Retained Earnings	-7,075.53	-7,009.59	-6,569.35	-5,438.19	-4,585.37	-3,727.09
Comprehensive Income	-26.99	-23.38	-44.65	-33.26	-43.62	-36.52
Shareholders' Equity	-219.27	-220.64	-158.22	588.2	1,016	1,439
Net Cash / Debt	1,070	1,134	872.16	1,438	1,353	1,232
Net Cash / Debt Growth	42.61%	30.02%	-39.35%	6.26%	9.81%	16.90%
Net Cash Per Share	8.48	9.08	7.17	12.14	11.77	11.28
Working Capital	2,047	2,015	1,924	2,113	2,030	1,363
Book Value Per Share	-1.74	-1.77	-1.30	4.97	8.84	13.17

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).